Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA Expands Emergency Use for Lilly Antibody Combination for Covid-19 to Include Infants

12/03/2021 | 03:18pm EST

By Josh Beckerman

The U.S. Food and Drug Administration expanded its emergency use authorization for a combination of two Eli Lilly & Co. monoclonal antibodies for treating mild to moderate Covid-19, expanding authorization to all ages including newborns for those who are at high risk for progression to severe Covid-19.

The combination of bamlanivimab and etesevimab was previously authorized for people 12 years of age and older weighing at least 40 kilograms.

Lilly said it is "working quickly to understand neutralization activity of our therapies on the Omicron variant of concern."

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

12-03-21 1518ET

All news about ELI LILLY AND COMPANY
01/25GLOBAL MARKETS LIVE : Credit Suisse, Unilever, Nvidia, Tesla, American Express...
01/25WALL STREET STOCK EXCHANGE : A roller-coaster week as Fed decision looms
01/25MARKETSCREENER’S WORLD PRESS REVIEW : January 25, 2022
01/24US FDA Restricts Use of Eli Lilly, Regeneron's COVID-19 Treatments
MT
01/24FDA to Restrict Monoclonal Antibodies Manufactured by Eli Lilly, Regeneron Pharmaceutic..
MT
01/24Morgan Stanley Adjusts Eli Lilly and Co.'s Price Target to $272 from $275, Keeps Overwe..
MT
01/21Innovent and Eli Lilly and Company Announces Final Clinical Results and Biomarker Analy..
CI
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21Alzheimer's patient groups protest U.S. Medicare coverage proposal limiting use of new ..
RE
01/21DZ Bank Upgrades Eli Lilly and Co. to Buy From Hold; Price Target is $291
MT
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 28 002 M - -
Net income 2021 6 022 M - -
Net Debt 2021 12 037 M - -
P/E ratio 2021 37,0x
Yield 2021 1,40%
Capitalization 216 B 216 B -
EV / Sales 2021 8,13x
EV / Sales 2022 8,04x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 237,86 $
Average target price 285,18 $
Spread / Average Target 19,9%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY-13.89%215 642
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
NOVO NORDISK A/S-14.94%215 777